Fresenius SE KGaA (FRE) Stock Overview
A health care company, provides products and services for chronically ill patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
FRE Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €50.02 |
| 52 Week High | €50.74 |
| 52 Week Low | €31.60 |
| Beta | 1.02 |
| 1 Month Change | 6.06% |
| 3 Month Change | 20.56% |
| 1 Year Change | 47.38% |
| 3 Year Change | 115.60% |
| 5 Year Change | 48.30% |
| Change since IPO | 4,330.50% |
Recent News & Updates
Recent updates
Fresenius SE KGaA (ETR:FRE) Will Be Hoping To Turn Its Returns On Capital Around
Sep 22
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Reasonably Well
Jul 06Investors Holding Back On Fresenius SE & Co. KGaA (ETR:FRE)
Jun 21This Is Why Fresenius SE & Co. KGaA's (ETR:FRE) CEO Compensation Looks Appropriate
May 17These Return Metrics Don't Make Fresenius SE KGaA (ETR:FRE) Look Too Strong
Apr 15Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?
Mar 31Why We're Not Concerned About Fresenius SE & Co. KGaA's (ETR:FRE) Share Price
Mar 15Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal
Jan 10Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?
Dec 20Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult
Nov 29
Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion
Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion.Shareholder Returns
| FRE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.1% | 1.0% | -1.4% |
| 1Y | 47.4% | 37.7% | 12.6% |
Return vs Industry: FRE exceeded the German Healthcare industry which returned 37.7% over the past year.
Return vs Market: FRE exceeded the German Market which returned 12.6% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 2.3% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FRE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 176,207 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €28.17b |
| Earnings (TTM) | €1.08b |
| Revenue (TTM) | €22.28b |
Is FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.28b |
| Cost of Revenue | €16.87b |
| Gross Profit | €5.41b |
| Other Expenses | €4.33b |
| Earnings | €1.08b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 24.28% |
| Net Profit Margin | 4.84% |
| Debt/Equity Ratio | 60.2% |
How did FRE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 07:52 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresenius SE & Co. KGaA is covered by 34 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bate | Barclays |
| Hassan Al-Wakeel | Barclays |
| Thomas Jones | Berenberg |